# Oligogen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oligogen

- Industry: Biotechnology
- Headquarters: Kyoto, Japan
- Website: www.oligogen.jp
- Total disclosed funding: $1M
- Latest round: Series A (Aug 1, 2017)
- Investors on record: 4

## About

Based in Kyoto, Japan, Oligogen, Inc. focuses on advancing regenerative medicine, specifically targeting neurological disorders through innovative therapies such as cell and exosome treatments.Founded in 2015 in Kyoto, Japan, Oligogen, Inc. specializes in developing therapies for neurological disorders. The company has undergone no major pivots in its strategy or operations and has not reported any subsidiaries. They secured JPY 111 million in Series A funding from investors including Kyoto University Innovation Capital, Nissay Capital, PF Capital, and SMBC Capital Partners on August 1, 2017, which represents the total amount they have raised to date. Although there is no information available on the founder's prior ventures, their expertise likely supports Oligogen's mission.Oligogen Inc. specializes in advanced regenerative medicine aimed at treating neurological disorders through innovative therapies. The company's core product offerings include cell therapy utilizing their proprietary neural stem cell technology, Oligogeny, and exosome therapy targeting conditions such as Alzheimer's disease and multiple sclerosis. These therapies leverage biotechnology and genetic research to provide customized treatments with minimal side effects, addressing unmet medical needs in neurodegenerative diseases. The end users of Oligogen's products primarily consist of healthcare providers and institutions involved in treating severe neurological conditions, with a growing commitment to collaborating with universities and pharmaceutical companies globally for research and development efforts. Oligogen’s products target markets across North America, Europe, and Asia.Oligogen Inc. generates revenue through partnerships with academic institutions and pharmaceutical companies, along with direct collaborations with healthcare providers. Their business model emphasizes B2B transactions, focusing on supplying innovative therapies to hospitals and clinics specializing in neurology. Pricing structures and financial arrangements connected to their flagship products, such as the Oligogeny stem cell treatment and proprietary exosome formulations, reflect the high-value nature of advanced regenerative therapies. These transactions are typically negotiated on a case-by-case basis, aligning with the customized nature of the treatments. Revenue is derived from the successful implementation of these therapies, based on their efficacy and safety in clinical settings, as well as potential licensing agreements for proprietary technologies.Oligogen, Inc. plans to utilize the JPY 111 million raised in Series A funding to enhance research and development of new treatments aimed at neurological disorders. The company is working on new product designs, particularly focusing on novel exosome therapies, although specific release dates have not been disclosed. In terms of market expansion, Oligogen aims to increase its presence in North America and Europe by 2025, targeting collaborations with more healthcare institutions and pharmaceutical partners. Through these initiatives, Oligogen seeks to broaden access to its innovative medical solutions and improve treatment outcomes for patients with neurological disorders.

## Funding rounds

- Series A, Aug 1, 2017, $1M — Nissay Capital, PF Capital, Kyoto University Innovation Capital, SMBC Capital Partners

## Investors

- Nissay Capital (https://capitalatlas.ai/funds/nissay-capital) — Series A
- PF Capital (https://capitalatlas.ai/funds/pf-capital) — Series A
- Kyoto University Innovation Capital (https://capitalatlas.ai/funds/kyoto-university-innovation-capital) — Series A
- SMBC Capital Partners (https://capitalatlas.ai/funds/smbc-capital-partners) — Series A